Eli Lilly collaborates with Precision BioSciences for genome editing research

▴ Eli Lilly collaborates with Precision BioSciences for genome editing research
This collaboration will help to accelerate the work aimed to solve genetic diseases with unique editing challenges

Eli Lilly and Company and Precision BioSciences, Inc. recently announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to make a variety of efficient edits (knock-in, knock-out, and repair), and small size, thereby enabling a range of therapeutic editing. The platform is derived from a natural genome-editing enzyme called I-CreI, a homing endonuclease that can be optimized to control for potency and specificity.

Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging from the mid-single digits to low-teens on product sales should Lilly successfully commercialize a therapy from the collaboration. Precision will lead pre-clinical research and IND-enabling activities, with Lilly then assuming responsibility for clinical development and commercialization. Lilly will have the right to select up to three additional gene targets for this collaboration. Precision can co-fund clinical development of one product in exchange for an increased royalty rate on co-funded product sales.

"Gene-edited therapies are emerging as a promising approach to help patients afflicted with genetic conditions," said Ruth Gimeno, Ph.D., vice president of diabetes and metabolic research at Lilly. "We look forward to working closely with Precision's scientific team and leveraging their platform to develop and deliver breakthrough medicines for untreated genetic disorders."

"This collaboration with Precision BioSciences represents another milestone in the realization of our vision to create medicines with transformational potential, using new therapeutic modalities such as gene editing to tackle targets and indications which were previously undruggable," added Andrew Adams, Ph.D., vice president of new therapeutic modalities at Lilly.

"We look forward to working with Lilly to leverage our deep understanding of in vivo gene editing and experience with ARCUS to develop new therapies, including a potentially transformative treatment for Duchenne muscular dystrophy," said Derek Jantz, chief scientific officer and co-founder of Precision BioSciences. "Collaborating with Lilly, a global healthcare leader with strong clinical and commercial experience in difficult-to-treat diseases, will help us accelerate our work aimed to solve genetic diseases with unique editing challenges."

This transaction is subject to clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act and other customary closing conditions. This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

Tags : #EliLilly #LatestNewsonEliLilly21stNov #PrecisionBioSciences #LatestNewsonPrecisionBioSciences21stNov #LatestPharmaNews21stNov #LatestPharmaCollaboration21stNov #LatestNewsonGenomeResearch21stNov

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Cancer on the Menu: How Excess Salt is Quietly Killing Your StomachDecember 03, 2024
Breaking Barriers: Honouring the International Day of Persons with Disabilities December 03, 2024
Invisible Threat: How Air Pollution is Impacting Pregnancies and Shaping Future GenerationsDecember 03, 2024
Medanta Gurugram successfully treats ‘rarest of rare’ lymph node cancer resistant to other drugs using CAR-T Cell TherapyDecember 03, 2024
Nonin Medical secures FDA clearance for its over-the-counter fingertip pulse oximeter, accurate for patients of all skin colorsDecember 02, 2024
ALARM 2024: Amrita Leads the Fight Against Antimicrobial ResistanceDecember 02, 2024
Coral adaptation unlikely to keep pace with global warmingDecember 02, 2024
Reaching the unreached to find missing TB casesDecember 02, 2024
Sip Smart: Why Changing Your Water Habits Can Change Your LifeNovember 28, 2024
Can Your Fingers Predict How Much You Drink? New Study ExplainsNovember 28, 2024
India Leads Global Medical Tourism with 8% Share; PSRI Sets New Benchmarks with nearly 15% International Patient BaseNovember 28, 2024
Medicines save lives but not when they stop workingNovember 28, 2024
A total of 340 Children Participated in the Painting Competition Organized by Asian HospitalNovember 28, 2024
The Standing Desk Myth: Is Sitting Actually Healthier?November 27, 2024
How Cancer Outsmarts Chemotherapy: The Hidden Metabolic GameNovember 27, 2024
Aakash Healthcare Saves life of a 61-year-old Women through Timely Neuro-intervention with a multi-disciplinary management of StrokeNovember 27, 2024
Breakfast Wars: Why Men and Women Should Eat DifferentlyNovember 27, 2024
Only 10% of Businesses Are Ready to Become Experience-Orchestrated, Highlighting Lack of PersonalisationNovember 27, 2024
Investors Think Safe, but Act Bold: MyFi Report Exposes Risk Tolerance Mismatch November 27, 2024
Indkal Technologies Redefines Luxury Home Entertainment with Acer M Series Hybrid MiniLED TelevisionsNovember 27, 2024